khaoula ★ Algeria, 2014-05-20 21:18 (4011 d 14:46 ago) Posting: # 12978 Views: 6,907 |
|
Hi everybody, I'm pharmacist doing my residency in pharmacology in Algeria, I prepare my post graduate disertation and the subject is the design of bioequivalence studies for Highly Variable Drug, I try to understand the two approche of EMA and FDA for HVDP: EMA:- does The European guideline prescribes a pilote study with replicate design to determine a CV withinsubject of the reference product to expand the limits in a pivotal replicate design study and apply the TOST with the news limits? - the sample size is determined with CV withinsubject of bibliography? FDA: what about the TOST ? or we juste apply mixed procedure for average BE? I dont understand what they do thank you very much and sorry I have a bad english ![]() |
d_labes ★★★ Berlin, Germany, 2014-05-22 16:24 (4009 d 19:41 ago) @ khaoula Posting: # 12989 Views: 5,780 |
|
Dear khaoula, ❝ ... I prepare my post graduate disertation and the subject is the design of bioequivalence studies for Highly Variable Drug, one of the main activity of a scientist, and you will become such a strange person, is reading papers of their colleges ![]() There are tons of papers out there dealing with your subject. I recommend: Read them! To get an understanding what in principle could be done scientifically. Read also the guidelines to notice what regulatory bodies left over from the scientific possibilities. Wish you good luck Detlew |
khaoula ★ Algeria, 2014-05-23 17:37 (4008 d 18:27 ago) @ d_labes Posting: # 12997 Views: 5,789 |
|
Dr Mr, I have read à lot of guidelines and Draft of(FDA, EMA)and some articles but I do not have access to lot of papers such as http://www.ncbi.nlm.nih.gov/pubmed/22162308 , so I can't understand for FDA approach application of SABE The test formulation is judged to be SABE with the reference product if the upper 95% confidence limit is <0 ![]() ![]() |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2014-05-23 19:11 (4008 d 16:53 ago) @ khaoula Posting: # 12998 Views: 5,818 |
|
Dear Khaoula, ❝ […] The test formulation is judged to be SABE with the reference product if the upper 95% confidence limit is <0 The general model (both for RSABE and ABEL) is (I) –θs ≤ (μT–μR)/σW ≤ θs. We can rearrange this inequation to(II) –θsσW ≤ μT–μR ≤ θsσW. That’s the model used by the EMA. The conventional 90% confidence interval should lie within the scaled (i.e., widended) acceptance limits. Therefore, the name of the method is Average Bioequivalence with Expanding Limits (ABEL).The FDA went another path. Start from (II) and square all sides in order to obtain: (III) θs²σW² ≤ (μT–μR)² ≤ θs²σW². Homework: ![]()
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
ElMaestro ★★★ Denmark, 2014-05-23 20:34 (4008 d 15:31 ago) @ Helmut Posting: # 12999 Views: 5,749 |
|
Hi Hötzi, ❝ The FDA went another path. Start from (II) and square all sides in order to obtain: (III) θs²σW² ≤ (μT–μR)² ≤ θs²σW². Excuse me? — Pass or fail! ElMaestro |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2014-05-24 01:44 (4008 d 10:21 ago) @ ElMaestro Posting: # 13003 Views: 5,734 |
|
Mon capitaine! ❝ ❝ θs²σW² ≤ (μT–μR)² ≤ θs²σW². ❝ Excuse me? Magnifique! Only proves that I’m lacking the most basic understanding of algebra. Go and get my pills now. ![]() — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
khaoula ★ Algeria, 2014-05-23 22:56 (4008 d 13:08 ago) @ Helmut Posting: # 13000 Views: 5,758 |
|
thank you Helmut, I understood how we have (μT – μR)2 – θs2·σW2 ≤ 0. first ![]() next ![]() and: ![]() but why the upper limit and CI at 95 % that's the question !! , I will search !! thank you verry much !! |